H.C. Wainwright Reiterates a Buy Rating on Citius Pharmaceuticals (CTXR)
In a report released today, Vernon Bernardino from H.C. Wainwright reiterated a Buy rating on Citius Pharmaceuticals (CTXR), with a price target of $4.00. The company’s shares closed last Friday at $2.03.
According to TipRanks.com, Bernardino is a 5-star analyst with an average return of 36.6% and a 41.4% success rate. Bernardino covers the Healthcare sector, focusing on stocks such as Viridian Therapeutics, Tenax Therapeutics, and Can-Fite BioPharma.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Citius Pharmaceuticals with a $5.00 average price target, representing a 147.5% upside. In a report issued on February 18, Dawson James also maintained a Buy rating on the stock with a $6.00 price target.
See today’s analyst top recommended stocks >>
Based on Citius Pharmaceuticals’ latest earnings release for the quarter ending December 31, the company reported a quarterly GAAP net loss of $8.15 million. In comparison, last year the company had a GAAP net loss of $4.32 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Citius Pharmaceuticals, Inc. engages in the development and commercialization of therapeutic products. It offers Mino-Lok, a patented solution to treat and salvage infected central venous catheters in patients with catheter related bloodstream infections and Hydro-Lido, a topical formulation of hydrocortisone and lidocaine that is intended for treatment of hemorrhoids. The company was founded by Ralph Montrone on January 23, 2007 and is headquartered in Cranford, NJ.